Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 16/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 13/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 6/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12709735 | 1.00 | MAOB (0.46) | MAOBMAOACYP2D6CYP1A2CYP1A1 | |
| SCHEMBL13551652 | 0.86 | CYP2D6 (0.45) | CYP2D6CYP1A2CYP1A1CYP1B1LMNA | |
| SCHEMBL12709734 | 0.81 | MAOB (0.48) | MAOBMAOACYP2D6CYP1A2CYP1A1 | |
| SCHEMBL13388482 | 0.81 | MAOB (0.48) | MAOBMAOACYP2D6CYP1A2CYP1A1 | |
| SCHEMBL13388494 | 0.81 | TUBB4A (0.42) | MAOBMAOACYP2D6CYP1A2CYP1A1 | |
| SCHEMBL13388496 | 0.81 | TUBB4A (0.42) | MAOBMAOACYP2D6CYP1A2CYP1A1 | |
| SCHEMBL13387797 | 0.80 | MAPT (0.47) | MAOBMAOANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12710006 | 0.80 | MAPT (0.47) | MAOBMAOANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13388440 | 0.80 | PFKFB3 (0.42) | MAOBCYP2D6CYP1A2CYP1A1CYP1B1 | |
| SCHEMBL12709763 | 0.80 | PFKFB3 (0.42) | MAOBCYP2D6CYP1A2CYP1A1CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916711-B2 | Imidazothiazole-chalcone derivatives as potential anticancer agents and process for the preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2014-12-23 | — | — | US | claimed |
| US-20120271054-A1 | IMIDAZOTHIAZOLE-CHALCONE DERIVATIVES AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2012-10-25 | — | — | US | claimed |
| US-8916711-B2 | Imidazothiazole-chalcone derivatives as potential anticancer agents and process for the preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2014-12-23 | — | — | US | disclosed |
| EP-2488533-B1 | IMIDAZOTHIAZOLE-CHALCONE DERIVATIVES AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2014-07-23 | — | — | EP | disclosed |
| US-20120271054-A1 | IMIDAZOTHIAZOLE-CHALCONE DERIVATIVES AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2012-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120271054-A1 | IMIDAZOTHIAZOLE-CHALCONE DERIVATIVES AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | EIF4A1, CYP2C18, UGT2B17 | MAOB 3130/4885MAOA 2044/4885CYP2D6 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.